Chemo testicular nonseminoma may increase risk of short-term CVD death
the ONA take:
Patients with testicular nonseminoma have significantly increased cardiovascular disease mortality after chemotherapy but not surgery, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
Previous research from the 1960s has shown that long-term survivors of testicular cancer who were treated with chemotherapy have increased risks of incidence cardiovascular disease, but there is a lack of data on whether treatment increases cardiovascular mortality during, shortly after, and for two decades after diagnosis in a time where most patients with testicular cancer receive cisplatin-based regimens.
For the study, researchers analyzed data from 15,006 patients with testicular nonseminoma from the Surveillance, Epidemiology, and End Results (SEER) database. Of those, 6,909 initially received chemotherapy and 8,097 initially underwent surgery without radiation.
Results showed that cardiovascular disease mortality was significantly increased after chemotherapy but not surgery. Researchers found that increased cardiovascular disease mortality was limited to the first year after testicular cancer diagnosis.
The authors conclude that the increased short-term risk of cardiovascular disease death should be investigated further in analytic studies.
Patients with testicular nonseminoma have significantly increased cardiovascular disease mortality after chemotherapy.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|